Peter Lio, MD

Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.

Experts in dermatology discuss which disease characteristics play the biggest role in influencing treatment choice or change of treatment from the perspective of a patient with atopic dermatitis.

A panel of expert dermatologists comments on newly approved and traditional treatment options, addressing how they target inflammation and the pathophysiology of atopic dermatitis (AD).

Experts in dermatology stress the importance of patient education in atopic dermatitis management and discuss their approaches to keeping patients up-to date.

Raj Chovatiya, MD, PhD; Brittany G. Craiglow, MD; and Peter A. Lio, MD, provide insight into emerging therapies and future directions in the management of pediatric atopic dermatitis.

Dr Peter A. Lio hypothesizes about the ability to induce remission in patients suffering from atopic dermatitis with the use of biologics and holistic treatment approaches.

Dr Brittany G. Craiglow reviews dosing considerations and nuances for the use of dupilumab for atopic dermatitis in pediatric populations.

Experts in dermatology review the indications and evolution of the use of dupilumab in patients with atopic dermatitis, highlighting its recent approval for patients 6 months and older.

Brittany G. Craiglow, MD, discusses the efficacy and safety of upadacitinib and describes her clinical experiences with this treatment.

Brittany G. Craiglow, MD, and Peter A. Lio, MD, provide insight into the efficacy and safety of currently available JAK inhibitors for the treatment of pediatric atopic dermatitis.

Raj Chovatiya, MD, PhD, highlights recent advances in pediatric atopic dermatitis treatments and discusses considerations regarding their use and indications.

Dr Peter A. Lio shares his advice for curating an atopic dermatitis treatment plan and explains the difference between rescue and maintenance treatments.

Dr Brittany G. Craiglow provides an overview of her approach to use of nonpharmacological agents in the treatment of her pediatric patients with atopic dermatitis.

Raj Chovatiya, MD, PhD, and Brittany G. Craiglow, MD, share their opinions on how they assess and what they define as treatment success in their pediatric patients suffering from atopic dermatitis.

Experts in dermatology review the treatment landscape for pediatric patients with atopic dermatitis.

Dr Brittany G. Craiglow discusses the impact of disease burden on both the patient and their caregivers, with a focus on how this burden evolves as a patient ages.

Brittany G. Craiglow, MD, and Peter A. Lio, MD, provide insight into the challenges inherent to an atopic dermatitis diagnosis, focusing on the role of diet and a patient’s clinical presentation.

Experts in dermatology comment on the heterogeneity of atopic dermatitis and how this affects clinical practice decisions, patient quality of life, and disease burden.

Raj Chovatiya, MD, PhD; Brittany G. Craiglow, MD; and Peter A. Lio, MD, provide insight into pediatric atopic dermatitis, focusing their discussion on the pathophysiology, prevalence, and disease symptomology.

Closing out their discussion on the management of atopic dermatitis, expert panelists share clinical pearls and key takeaways from their discussion.

Shared insight on the best ways to educate patients on their atopic dermatitis and explain the nuances of available therapies.

A broad look at the ongoing challenges and unmet needs in the field of atopic dermatitis management.

Marc Serota, MD, elucidates the heterogeneity of atopic dermatitis and explains how this can contribute to challenges in treating patients.

Expert panelists share excitement for novel therapies in the pipeline for the management of atopic dermatitis.

Taking into account all available topical and systemic therapies, Marc Serota, MD, provides his optimal sequencing strategy for patients with atopic dermatitis.

Drs. Lio, Feldman and Jain reflect on the adverse event profile of JAK inhibitor therapy in atopic dermatitis and consider when these agents are appropriate for use.

An overview of the three JAK inhibitor therapies available for the management of atopic dermatitis.

Expert perspectives on the interleukin pathway inhibitors, dupilumab and tralokinumab, and their role in managing atopic dermatitis.

A brief discussion on how the coronavirus 2019 pandemic has impacted the management of patients with atopic dermatitis.

Considerations for managing mild-to-moderate versus moderate-to-severe atopic dermatitis and which therapies are appropriate in each setting.